DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC
Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.
United States Martin Wermke University Hospital Carl Gustav Carus American Society Of Clinical Oncology Early Clinical Trial Unit National Center
Source: onclive.com